Air Products & Chemicals Management Discusses Q2 2012 Results - Earnings Call Transcript

Air Products & Chemicals (APD)

Q2 2012 Earnings Call

April 24, 2012 10:00 am ET


Simon R. Moore - Former Director of Investor Relations

Paul E. Huck - Chief Financial Officer and Senior Vice President


John Hirt

Jeffrey J. Zekauskas - JP Morgan Chase & Co, Research Division

James Sheehan - Deutsche Bank AG, Research Division

Brian Maguire - Goldman Sachs Group Inc., Research Division

Laurence Alexander - Jefferies & Company, Inc., Research Division

Christopher Perella

Vincent Andrews - Morgan Stanley, Research Division

Donald Carson - Susquehanna Financial Group, LLLP, Research Division

Michael J. Sison - KeyBanc Capital Markets Inc., Research Division

Abhiram Rajendran - Crédit Suisse AG, Research Division

Edward H. Yang - Oppenheimer & Co. Inc., Research Division

Mark Gulley



Good morning, and welcome to the Air Products and Chemicals Second Quarter Earnings Release Conference Call. [Operator Instructions] Also, this telephone conference presentation and the comments made on behalf of Air Products are subject to copyright by Air Products, and all rights are reserved. Air Products will be recording this teleconference and may publish all or a portion of the teleconference. No other recording or redistribution of this telephone conference by any other party is permitted without the express written permission of Air Products. Your participation indicates your agreement.

Beginning today's call is Mr. Simon Moore, Director of Investor Relations. Mr. Moore, you may begin.

Simon R. Moore

Thank you, Deanna. Good morning, and welcome to Air Products Second Quarter Earnings Teleconference. This is Simon Moore. Today, our CFO, Paul Huck, and I will review our Q2 results and outlook for the remainder of 2012.

We issued our earnings release this morning. It is available on our website along with the slides for this teleconference. Please go to to access the materials. Instructions for accessing the replay of this call beginning at 2 p.m. Eastern Time are also available on our website.

Please turn to Slide 2. As always, today's teleconference will contain forward-looking statements based on current expectations and assumptions. Please review the information on these slides and at the end of today's earnings release, explaining factors that may affect these expectations.

Now I'll turn the call over to Paul for a review of our financials.

Paul E. Huck

Thanks, Simon. Good day, everyone, and thanks for joining us. Please turn to Slide #3. Before we get into this quarter's operating results, I want to spend a few moments reviewing a few items impacting this quarter's numbers.

First, as we announced last quarter, we are in the process of divesting our European Homecare business, and as a result, we are now reporting this business in discontinued operations. As a reminder, European Homecare contributed $0.10 to our fiscal quarter 1. If we adjust our previously provided guidance for moving Homecare to discontinued operations, it would reduce quarter 2 by $0.09 and the full year by $0.30. Specifically, quarter 2 guidance adjusts to $1.28 to $1.34, and full year guidance adjust to $5.60 to $6.

The sale of our Continental European Homecare business has been approved by the European Commission, and we expect to close next week. Our quarter 3 results will reflect an after-tax gain in the range of EUR 105 million to EUR 130 million or approximately $140 million to $170 million from this transaction. We continue to work towards completing the divestiture of the remaining European Homecare business located primarily in the U.K.

We also recorded a cost reduction charge of approximately $60 million after-tax or $0.28 per share. This charge represents the ongoing actions we are taking to improve our cost structure, particularly in Europe. It includes removing the stranded costs resulting from our decision to exit the Homecare business and the actions we are taking to rightsize our European cost structure in light of the challenging economic outlook.

This charge includes a severance cost for the elimination of about 600 positions, primarily in Europe, and the write-down of 2 small plants. Most of the position elimination should be completed by the end of the fiscal year. In quarter 4, the savings should offset the approximately $6 million of quarterly stranded costs generated by the Homecare divestiture. When fully implemented, we expect the cost reduction plan to provide $60 million of annual savings.

Third, we recorded a tax gain of $58 million or $0.27 per share for a disputed tax item which was finally resolved. This item dates back almost 20 years in Spain. There is no cash impact. And as you can see from a book basis, this essentially offsets the impact of our cost reduction charge this quarter.

Excluding these items, our adjusted non-GAAP earnings per share from continuing operations is $1.31 for the quarter. As I mentioned, the comparable range for our previous quarter 2 guidance is $1.28 to $1.34. The comparable results for quarter 2 fiscal '11 were $1.33, and for quarter 1 fiscal '12 was $1.26.

Now let's turn to our operating results. Please turn to Slide #4. Overall, the quarter was within our expectations. However, our volumes did not grow through the quarter as we had expected. For the quarter, sales of $2.3 billion were 2% lower versus prior year, primarily due to lower energy pass-through and a stronger dollar.

Underlying sales increased 2% year-on-year, with both volume and price contributing 1% each. Higher tonnage volumes in both the refining and steel markets were partially offset by lower volumes in Merchant Gases and electronics. Pricing gains were recorded broadly across our merchant segment.

Read the rest of this transcript for free on